Effect of Repeated Exposures to Compressed Air on Patients With AIDS (DANET1)
This study has suspended participant recruitment.
(Change in institutional headquarters for the US study.)
Sponsor:
Designed Altobaric Technology, Incorporated
Information provided by:
Designed Altobaric Technology, Incorporated
ClinicalTrials.gov Identifier:
NCT00444847
First received: March 7, 2007
Last updated: April 2, 2007
Last verified: March 2007
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The exposure of human beings to markedly altered environments (ambient pressure and inhaled gas mixtures) has profound effects on their innate immune capacity to effectively combat viral illnesses. This Phase IIA clinical trial examines the effects of an exposure to a 4 atmospheric environment has on HIV-infected humans whose clinical condition has progressed to formal AIDS status.
| Condition | Intervention | Phase |
|---|---|---|
|
AIDS |
Device: Hyperbaric chamber |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Crossover Assignment Masking: Single Blind Primary Purpose: Treatment |
| Official Title: | Effect of Repeated Exposure to Compressed Air on Patients With AIDS (Acquired Immunodeficiency Syndrome) |
Resource links provided by NLM:
Genetics Home Reference related topics:
complement factor I deficiency
MedlinePlus related topics:
HIV/AIDS
U.S. FDA Resources
Further study details as provided by Designed Altobaric Technology, Incorporated:
Eligibility| Ages Eligible for Study: | 18 Years to 70 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- CD4 count <200
- Viral load > 5000
Exclusion Criteria:
- Opportunistic infection
- Concurrent neoplasm (see protocol)
- Immunomodulators
- HIV vaccination
- Investigational HIV drugs (see protocol)
- Pregnant women
- Major organ transplant
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00444847
Locations
| United States, Michigan | |
| Detroit Receiving Hospital | |
| Detroit, Michigan, United States, 48201 | |
Sponsors and Collaborators
Designed Altobaric Technology, Incorporated
Investigators
| Principal Investigator: | Stephen D. Guthrie, MD, PhD | Designed Altobaric Environment Technology |
| Principal Investigator: | Stephen G Guthrie, MD, PhD | Designed Altobaric Environment Technology |
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00444847 History of Changes |
| Other Study ID Numbers: | DANET HIV/AIDS Trial Q050021, FDA Q050021 |
| Study First Received: | March 7, 2007 |
| Last Updated: | April 2, 2007 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Designed Altobaric Technology, Incorporated:
|
AIDS HIV Hyperbaric Chamber treatment experienced |
Additional relevant MeSH terms:
|
Acquired Immunodeficiency Syndrome HIV Infections Immunologic Deficiency Syndromes Lentivirus Infections Retroviridae Infections RNA Virus Infections |
Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Slow Virus Diseases Immune System Diseases |
ClinicalTrials.gov processed this record on May 16, 2013